首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119
【24h】

The optimization of xanthine derivatives leading to HBK001 hydrochloride as a potent dual ligand targeting DPP-IV and GPR119

机译:优化黄嘌呤衍生物,导致HBK001盐酸盐作为靶向DPP-IV和GPR119的有效双配体

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

A series of xanthine compounds derived from the previous hit 20i with modification on the terminal side chain was discovered through ring formation strategy. Systematic optimization of the compounds with rigid heterocycles in the hydrophobic side chain led to the new lead compound HBK001 (21h) with the improved DPP-IV inhibition and moderate GPR119 agonism activity in vitro. As a continuing work to further study the PK and PD profiles, 21h and its hydrochloride (22) were synthesized on grams scale and evaluated on the ADME/T and oral glucose tolerance test (OGTT) in ICR mice. Compound 22 showed the improved bioavailability and blood glucose-lowering effect in vivo compared to its free base 21h probably attributed to its improved solubility and permeability. The preliminary toxicity studies on compound 22 exhibited that the result of mini-Ames was negative and the preliminary acute toxicity LD50 in mice was above 1.5 g/kg, while it showed moderate inhibition on hERG channel with IC50 4.9 mu M maybe due to its high lipophilicity. These findings will be useful for the future drug design for more potent and safer dual ligand targeting DPP-IV and GPR119 for the treatment of diabetes. (C) 2020 Elsevier Masson SAS. All rights reserved.
机译:通过环形形成策略发现了一系列从先前的MIT 20i衍生自前侧链的末端侧链的悬垂化合物。在疏水侧链中具有刚性杂环的化合物的系统优化L导出到新的铅化合物HBK001(21h),其具有改善的DPP-IV抑制和中度GPR119激动活性在体外。作为进一步研究PK和Pd型材的持续工作,在克拉尺度上合成21h及其盐酸盐(22),并在ICR小鼠中评估了ICE / T和口服葡萄糖耐量试验(OGTT)。与其自由基碱21h相比,化合物22显示了体内的改善的生物利用度和血糖降低效果,其可能归因于其提高的溶解度和渗透性。化合物22的初步毒性研究表明,迷你ames的结果为阴性,小鼠中的初步急性毒性Ld50高于1.5克/千克,而IC50 4.9 mu m对Herg沟道上的中度抑制可能是由于其高度亲脂性。这些发现对于更有效和更安全的双配体的未来药物设计将用于靶向DPP-IV和GPR119,用于治疗糖尿病。 (c)2020 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号